AUDUBON, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2025. Worldwide net sales were $769.0 million, an increase of 22.9%, or an increase of 22.3% on a constant currency basisBase business, excluding Nevro, net sales were $669.8 million, an increase of 7.0%, or an increase of 6.5% on a constant currency basisGAAP net income for the quarter was $119.0 millionGAAP ...

Gross margin decreased 400 basis points year-over-year to 39.7%Reported net loss of $4 million, adjusted EBITDA1 of $1.4 millionNet sales of $81.6 million FORT WORTH, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Farmer Brothers Coffee Co. (NASDAQ: FARM), a leading roaster, wholesaler and distributor of coffee, tea and allied products, announced today its first quarter fiscal 2026 financial results for the period ended Sept. 30, 2025. The company filed its Form 10-Q, which will be posted on the Investor Relation ...

Core Insights - AMN Healthcare Services reported third quarter 2025 revenue of $634 million, an 8% decrease year-over-year, with adjusted EBITDA of $58 million, reflecting a 22% decline from the previous year [1][4][10] - The company achieved a net income of $29 million, significantly up from $7 million in Q3 2024, resulting in diluted earnings per share of $0.76 compared to $0.18 a year ago [1][4][10] - The company anticipates fourth quarter 2025 revenue to be between $715 million and $730 million, with expectations of a sequential increase in travel nursing demand [14][15] Financial Performance - Consolidated revenue for Q3 2025 was $634.5 million, down 8% from Q3 2024 and down 4% from Q2 2025 [1][4] - Gross profit for the quarter was $184.4 million, a 13% decrease year-over-year, with a gross margin of 29.1% [1][9] - Adjusted diluted EPS was $0.39, down 36% from $0.61 in Q3 2024 [1][10] Segment Performance - Nurse and Allied Solutions segment revenue was $361 million, a 9% decrease year-over-year, with travel nurse staffing revenue down 20% [5][36] - Physician and Leadership Solutions segment reported revenue of $178 million, down 1% year-over-year, while locum tenens revenue increased by 3% [6][36] - Technology and Workforce Solutions segment revenue was $95 million, a decrease of 12% year-over-year, primarily due to the sale of Smart Square scheduling software [8][36] Operational Highlights - Cash flow from operations was $23 million, and the company paid off its revolving line of credit with proceeds from the sale of Smart Square totaling $65 million [6][11] - The company refinanced its senior unsecured notes due in 2027 with new notes due in 2031, enhancing financial flexibility [12][13] - Staffing orders rebounded in Q3, with winter order volume higher than the previous year, indicating potential growth in travel nursing for Q4 [4][6] Guidance and Outlook - For Q4 2025, the company expects revenue to be 1-3% lower than the prior year but up 13-15% sequentially [15] - Labor disruption revenue is projected at approximately $100 million, compared to $62 million in the prior-year quarter [15] - The company anticipates a gross margin of 25.5% to 26.0% for Q4, reflecting a decrease due to lower margins on labor disruption revenue [14][15]

Third Quarter Financial Highlights: Total revenues decreased $26.2 million year over year to $422.6 million Material Handling revenues decreased $1.0 million year over year to $167.9 million, while Construction Equipment and Master Distribution revenues decreased a combined $23.9 million year over year to $256.6 millionProduct support revenues increased 1.1% year over year to $141.7 million for the quarterProduct support gross profit percentage increased 160 basis points year over year to 47.2%Selling, gen ...

Increased Quarterly Sales 3% and Adjusted EBITDA 15%Adventure Reported Sales up 16%Apparel Sales at Outdoor up 29% SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Clarus Corporation (NASDAQ: CLAR) (“Clarus” and/or the “Company”), a global company focused on the outdoor enthusiast markets, reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Summary vs. Same Year‐Ago Quarter Sales of $69.3 million compared to $67.1 million.Gross margin was 35.1% compared t ...

Net sales of $1.140 billion, increased 6.0% sequentially and declined 2.0% from the year ago quarter. The midpoint of our guidance provided on August 7, 2025 was net sales of $1.130 billion.On a GAAP basis: gross profit of 55.9%; operating income of $88.9 million and 7.8% of net sales; net income attributable to common stockholders of $13.9 million; and EPS of $0.03 per diluted share. Our guidance provided on August 7, 2025 was for GAAP EPS loss per diluted share of $0.04 to $0.01.On a Non-GAAP basis: gross ...

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- DraftKings Inc. (Nasdaq: DKNG) (“DraftKings” or the “Company”) today announced its third quarter 2025 financial results. The Company also posted a third quarter 2025 business update and a slide presentation on the Investor Relations section of its website at investors.draftkings.com. Third Quarter 2025 HighlightsFor the three months ended September 30, 2025, DraftKings reported revenue of $1,144 million, an increase of $49 million, or 4%, compared to $1,095 million ...

Management to Host Conference Call on Thursday, November 13, 2025, at 9:00 a.m. Eastern timeBALLERUP, Denmark, Nov. 06, 2025 (GLOBE NEWSWIRE) -- LiqTech International, Inc. (NASDAQ: LIQT), a high-tech filtration company that manufactures and markets highly specialized filtration products and systems, will report third quarter 2025 financial results for the period ended September 30, 2025, on Thursday, November 13, 2025, before the market opens. The Company has scheduled a conference call that same day, Thur ...

Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced issuance of new U.S. patent covering crystalline salts and co-crystals forms of cadisegliatin with exclusivity expected out to 2041 HIGH POINT, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, ...

Core Insights - The E.W. Scripps Company reported $526 million in revenue for Q3 2025, a decrease of 19% or $120 million from the previous year [6][24] - The company experienced a loss attributable to shareholders of $49 million, equating to 55 cents per share, compared to a profit of $33 million or 37 cents per share in the prior-year quarter [7][24] - Scripps has successfully reduced its leverage ratio to 4.6x by the end of Q3 2025, down from 4.9x at the start of the year [3][12] Financial Performance - Local Media segment revenue was $325 million, down 27% from the prior-year quarter, with segment profit dropping to $52.8 million from $161 million [8][9] - Scripps Networks segment revenue was $201 million, a slight decrease of 0.4%, but segment profit increased to $53.3 million from $42.1 million [10][34] - Total costs and expenses for the company decreased to $449 million from $472 million in the year-ago quarter [6][24] Strategic Initiatives - The company has focused on expense discipline, achieving a reduction of over 4% in Local Media and 7.5% in Scripps Networks [4][5] - Scripps announced the sale of two stations for $123 million, which is above industry average valuations, contributing to a healthier balance sheet [3][5] - The company is leveraging sports partnerships and programming to drive growth, with core advertising revenue in Local Media up 2% in Q3 [5][14] Future Outlook - For Q4 2025, Local Media revenue is expected to decline by about 30%, while Scripps Networks revenue is projected to decrease in the low double-digit percentage range [18] - The company anticipates strong core revenue growth in Q4, supported by new agreements and continued growth in live sports markets [5][18] - Scripps is committed to optimizing its portfolio and embracing technology to enhance operational efficiencies [6][3]